Motowo Nakajima Selected Research

CGS 27023A

1/2008	Matrix metalloproteinase inhibitor, MMI270 (CGS27023A) inhibited hematogenic metastasis of B16 melanoma cells in both experimental and spontaneous metastasis models.
1/2006	Efficacy of the MMP inhibitor MMI270 against lung metastasis following removal of orthotopically transplanted human colon cancer in rat.
6/2004	In vivo trafficking of endothelial progenitor cells their possible involvement in the tumor neovascularization.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Motowo Nakajima Research Topics

Disease

54	Neoplasms (Cancer) 05/2022 - 04/2002
15	Neoplasm Metastasis (Metastasis) 07/2014 - 11/2002
12	Inflammation (Inflammations) 05/2022 - 11/2002
7	Stomach Neoplasms (Stomach Cancer) 03/2015 - 05/2003
6	Melanoma (Melanoma, Malignant) 07/2021 - 03/2004
5	Carcinoma (Carcinomatosis) 05/2022 - 08/2004
5	Esophageal Neoplasms (Esophageal Cancer) 01/2013 - 10/2004
4	Lymphatic Metastasis 01/2008 - 05/2003
3	Body Weight (Weight, Body) 01/2019 - 01/2017
3	Glucose Intolerance 01/2018 - 01/2017
3	Hypoxia (Hypoxemia) 10/2016 - 01/2015
3	Reperfusion Injury 02/2016 - 02/2015
3	Colorectal Neoplasms (Colorectal Cancer) 01/2016 - 03/2013
3	Breast Neoplasms (Breast Cancer) 07/2008 - 05/2005
3	Leukemia 04/2007 - 12/2003
2	Graft vs Host Disease (Graft-Versus-Host Disease) 01/2021 - 10/2018
2	Obesity 01/2019 - 01/2017
2	Fibrosis (Cirrhosis) 01/2019 - 10/2018
2	Type 2 Diabetes Mellitus (MODY) 01/2019 - 01/2016
2	Bone Diseases (Bone Disease) 01/2018 - 11/2017
2	Ischemia 10/2016 - 01/2016
2	Malaria 11/2015 - 12/2013
2	Colonic Neoplasms (Colon Cancer) 03/2013 - 01/2006
2	Dentigerous Cyst 05/2008 - 10/2007
2	Odontogenic Cysts (Keratocyst) 05/2008 - 10/2007
2	Odontogenic Tumors (Dental Tissue Neoplasm) 05/2008 - 10/2007
2	Experimental Melanoma 02/2008 - 01/2008
2	Neoplasm Micrometastasis 02/2008 - 01/2008
1	Hypogonadism (Hypergonadotropic Hypogonadism) 07/2022
1	COVID-19 01/2022
1	Bronchiolitis Obliterans Syndrome 07/2021
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 07/2021
1	Autoimmune Diseases (Autoimmune Disease) 07/2021
1	Lupus Nephritis 07/2021
1	Uterine Cervical Dysplasia 12/2020
1	Atherosclerotic Plaque (Atheroma) 12/2019
1	Immune System Diseases (Immune Disorders) 01/2019

Drug/Important Bio-Agent (IBA)

34	AcidsIBA 07/2022 - 03/2011
24	heparanaseIBA 05/2022 - 11/2002
15	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2003
14	protoporphyrin IXIBA 05/2021 - 03/2011
12	ferrous citrate FDA Link 07/2021 - 11/2015
11	1-phenyl-3,3-dimethyltriazene (PDT)IBA 05/2021 - 03/2011
9	Messenger RNA (mRNA)IBA 01/2021 - 03/2003
9	Heme (Haem)IBA 01/2019 - 03/2011
9	EnzymesIBA 01/2015 - 11/2002
8	GlucuronidaseIBA 05/2022 - 11/2002
8	Heparitin Sulfate (Heparan Sulfate)IBA 06/2016 - 11/2002
6	Biological ProductsIBA 05/2022 - 04/2002
5	Matrix Metalloproteinases (MMPs)IBA 01/2008 - 04/2002
4	Pharmaceutical PreparationsIBA 11/2017 - 12/2003
4	PorphyrinsIBA 11/2016 - 12/2011
3	LigandsIBA 07/2021 - 12/2003
3	Aminolevulinic Acid (Levulan)FDA Link 05/2021 - 09/2019
3	Adenosine Triphosphate (ATP)IBA 01/2019 - 09/2012
3	IronIBA 10/2018 - 01/2015
3	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2016 - 01/2015
3	Heparan Sulfate Proteoglycans (Heparan Sulfate Proteoglycan)IBA 06/2016 - 03/2004
3	Photosensitizing Agents (Photosensitizers)IBA 01/2015 - 11/2013
3	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 10/2012 - 11/2005
3	CGS 27023AIBA 01/2008 - 06/2004
3	Matrix Metalloproteinase InhibitorsIBA 01/2008 - 04/2002
2	Therapeutic UsesIBA 01/2022 - 12/2011
2	ChemokinesIBA 01/2021 - 01/2016
2	Heme Oxygenase-1IBA 12/2019 - 10/2016
2	LipidsIBA 12/2019 - 01/2019
2	Singlet OxygenIBA 01/2019 - 03/2011
2	Blood Glucose (Blood Sugar)IBA 01/2019 - 01/2017
2	Peptides (Polypeptides)IBA 06/2016 - 09/2012
2	ProdrugsIBA 01/2015 - 01/2015
2	Heparin (Liquaemin)FDA LinkGeneric 01/2013 - 11/2002
2	Phosphotransferases (Kinase)IBA 07/2009 - 12/2003
2	Small Interfering RNA (siRNA)IBA 07/2009 - 07/2008
2	Focal Adhesion Protein-Tyrosine KinasesIBA 07/2009 - 07/2008
2	Proteoglycans (Proteoglycan)IBA 05/2008 - 03/2003
2	perlecanIBA 05/2008 - 03/2003
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2008 - 08/2004
2	Collagen Type IV (Type IV Collagen)IBA 07/2006 - 03/2003
2	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2006 - 10/2004
2	Catalytic RNA (Ribozymes)IBA 03/2004 - 05/2003
1	Hyaluronic Acid (Hyaluronan)IBA 05/2022
1	tranilastIBA 01/2022
1	Antiviral Agents (Antivirals)IBA 01/2022
1	InflammasomesIBA 01/2022
1	AutoantibodiesIBA 07/2021
1	CytokinesIBA 01/2021
1	LDL Receptors (LDL Receptor)IBA 12/2019
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 11/2019
1	CreatinineIBA 01/2019
1	Dynamin IIIBA 01/2019
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2019
1	Heme Oxygenase (Decyclizing) (Heme Oxygenase)IBA 01/2019
1	Urea (Carbamide)FDA LinkGeneric 01/2019
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2019

Therapy/Procedure

16	Therapeutics 01/2022 - 05/2003
12	Photochemotherapy (Photodynamic Therapy) 05/2021 - 03/2011
2	Immunotherapy 07/2021 - 03/2011
2	Oral Administration 01/2017 - 12/2011
1	Drug Therapy (Chemotherapy) 05/2021
1	Hematopoietic Stem Cell Transplantation 01/2021